Recommended duration of dual antiplatelet therapy during follow-up
| Variable | All patients | Stable CAD | ACS | p Value Stable CAD vs ACS |
| No of patients | 2877 | 1793 | 1084 | – |
| DAPT duration in months | 10.0±2.8 | 9.4±2.9 | 11.0±2.2 | <0.001 |
| 1 month, n (%) | 24 (0.9) | 17 (0.9) | 7 (0.6) | <0.001 |
| 1–3 months, n (%) | 34 (1.2) | 24 (1.3) | 10 (0.9) | |
| 3–6 months, n (%) | 12 (0.4) | 8 (0.4) | 4 (0.4) | |
| 6 months, n (%) | 503 (17.5) | 416 (23.2) | 87 (8.0) | |
| >6–12 months, n (%) | 282 (9.8) | 210 (11.7) | 72 (6.6) | |
| 12 months, n (%) | 1524 (53.0) | 761 (42.4) | 763 (70.4) | |
| >12 months, n (%) | 5 (0.2) | 3 (0.2) | 2 (0.2) | |
| Unknown status, n (%) | 493 (17.1) | 354 (19.7) | 139 (12.8) |
ACS, acute coronary syndrome; CAD, coronary artery disease; DAPT, dual-antiplatelet therapy.